The Canada Medicines Agency recommends that public drug plans take care of treatment that has been shown to be effective in slowing the progression of Alzheimer's disease at an early stage, if patients meet certain conditions.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
The Canada Medicines Agency recommends that public drug plans take care of treatment that has been shown to be effective in slowing the progression of Alzheimer's disease at an early stage, if patients meet certain conditions.